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Abstract 
Background: Several studies have revealed that glucose fluctuations provoke oxidative stress that leads to endothe‑
lial cell dysfunction, progression of coronary atherosclerosis, and plaque vulnerability. However, little is known 
regarding their effect on neointimal growth after stenting in patients with coronary artery disease (CAD). We aimed to 
investigate the effects of glucose fluctuations on neointimal growth after everolimus‑eluting stent (EES) implantation.
Methods: This study examined 50 patients who underwent a 9‑month follow‑up using optical coherence tomogra‑
phy (OCT) after EES implantation. Glucose fluctuation was expressed as the mean amplitude of glycemic excursion 
(MAGE), and was determined via continuous glucose monitoring before stenting. At the OCT follow‑up, we evaluated 
the percentage of uncovered struts and three‑dimensional uniformity of neointimal distribution by calculating the 
mean neointimal thickness (NIT) within 360 equally‑spaced radial sectors for every 1‑mm cross‑sectional OCT analysis, 
and assessed the incidence of major adverse cardiovascular events (MACE).
Results: We evaluated 60 lesions in 50 patients. Linear mixed effect models were used to explore the influence of 
different variables on variability in NIT and the percentage of uncovered struts and to adjust for covariates. Univariate 
analysis showed that MAGE was most strongly correlated with the previously mentioned OCT measurements (coeffi‑
cient β ± standard error = 0.267 ± 0.073 and 0.016 ± 0.003, t = 3.668 and 6.092, both P < 0.001, respectively). In mul‑
tivariate analysis, MAGE had the strongest effect on variability in NIT (coefficient β ± standard error = 0.239 ± 0.093, 
P = 0.014) and the percentage of uncovered struts (coefficient β ± standard error = 0.019 ± 0.004, P < 0.001). 
Five lesions in four patients required target lesion revascularization (10.0 %) at a mean duration of 9 months after 
EES implantation. Compared to non‑MACE cases, cases of MACE exhibited a significantly higher MAGE (99 vs. 68; 
P = 0.004), maximum NIT (580 vs. 330 µm; P = 0.002), and variability in NIT (100 vs. 65; P = 0.007), although there was 
no significant difference in these groups’ HbA1c levels.
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Background
Dyslipidemia, and especially high levels of low-density 
lipoprotein (LDL) cholesterol, has been recognized as 
one of the most important promoters of late-phase stent 
restenosis. A large number of clinical trials have reported 
the beneficial effects of statins for secondary prevention 
and improved all-cause mortality, as well as for lowering 
LDL cholesterol levels [1, 2]. However, the limited ability 
of risk reduction associated with lipid-lowering therapy 
alone has attracted attention to the unmet need for resid-
ual clinical risk management that extends beyond statin 
use.
Patients with diabetes mellitus (DM) have a particularly 
high risk of restenosis and target lesion revasculariza-
tion (TLR), compared to patients without DM [3, 4]. One 
of the possible mechanisms for this increased risk was 
thought to be diffuse and accelerated neointimal prolifer-
ation within the stented segment [5]. Although the intro-
duction of second-generation drug-eluting stents (DES), 
such as the everolimus-eluting stent (EES), has mark-
edly reduced the incidence of early- and late-phase stent 
restenosis, the presence of DM is still associated with an 
increased risk of restenosis and poor clinical outcomes 
after percutaneous coronary intervention (PCI) [6, 7]. 
However, the detailed vascular responses to EES implan-
tation among patients with impaired glucose metabolism 
has not been fully elucidated.
Sustained hyperglycemia is the underline condition 
in patients with DM, especially in its advanced stage. 
Recent studies have revealed that, not only continuous 
hyperglycemia, but also large glucose fluctuations, such 
as postprandial hyperglycemia, should be a deleterious 
factor that drive cardiovascular disease [8–11]. In-vitro 
analysis have shown that glucose fluctuations may exhibit 
a more specific triggering effect on oxidative stress and 
have adverse effects on human endothelial cells [8, 12]. 
The recent emergence of continuous glucose monitor-
ing (CGM) systems has made it possible to evaluate daily 
glucose fluctuations in clinical practice. Although insu-
lin resistance might affect neointimal tissue prolifera-
tion after 2nd-generation DES implantation, it remains 
unclear whether glucose fluctuations may affect vessel 
healing after stent deployment [13].
Numerous reports have described optical coherence 
tomography (OCT) as a high-resolution intravascular 
imaging modality that enables detailed assessments of 
the neointimal proliferation after stenting and plaque 
character [14, 15]. The present study aimed to investigate 
the relationship between glucose fluctuations and the 
arterial response after stenting, which we analyzed using 
CGM and OCT, respectively.
Methods
Patient population
A previous study [16] enrolled 70 consecutive patients 
who had undergone PCI using a drug-eluting stent for 
CAD between June 2012 and May 2014. These patients’ 
LDL cholesterol levels were  <120  mg/dL under statin 
treatment, or  <100  mg/dL under other treatments for 
dyslipidemia, which included lifestyle management. For 
the present study, we evaluate only patients who were 
treated using EES. The exclusion criteria for the present 
study were: (1) treatment with any other kind of stent; (2) 
unsuitable anatomy for OCT analysis in the stented seg-
ment; (3) severe renal dysfunction; (4) any change in the 
interventions for controlling diabetes, lipids, and hyper-
tension during the study period; and (5) the patients with 
any antidiabetic medications other than life-style manage-
ment after the CGM. In total, we enrolled 50 patients who 
treated with EES and were followed-up after 9  months 
via OCT (Fig. 1). In addition, we divided the patients into 
groups of patients with and without DM.
This study was approved by the ethics committee of 
Kobe University, and was performed in accordance with 
the tenets of the Declaration of Helsinki. All enrolled 
patients provided their written informed consent for 
enrollment in the study.
Study protocol
At the index stent procedure, a fasting blood sample was 
obtained and submitted for testing to evaluate the levels 
of creatinine, glycosylated hemoglobin (HbA1c), LDL 
cholesterol, high-density lipoprotein (HDL) cholesterol, 
and triglycerides. In addition, a 75-g oral glucose toler-
ance test was performed for all patients, and the levels of 
plasma glucose and immunoreactive insulin were evalu-
ated immediately before and 120 min after the oral glu-
cose load. Subcutaneous interstitial glucose levels were 
monitored over a 3-day period using the CGM System 
iPro™2 (Medtronic, Northridge, CA, USA).
Conclusions: Glucose fluctuation may affect vessel healing after EES implantation in patients with CAD who are 
receiving lipid‑lowering therapy. Therefore, glucose fluctuations may be an important target for secondary prevention 
after coronary stenting, which is independent of dyslipidemia control.
Keywords: Glucose fluctuation, Continuous glucose monitoring, Mean amplitude of glycemic excursion, Optical 
coherence tomography
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After the CGM examination, all patients underwent a 
catheterization procedure for PCI in the native coronary 
arteries, which was guided by intravascular ultrasound 
(IVUS) (Eagle Eye® Platinum 3.5F 20-MHz; Volcano 
Corp, Rancho Cordova, CA, USA) and were treated using 
EES implantation. The IVUS procedure was performed 
in a standard manner, which used an automated motor-
ized 0.5  mm/s pullback. Culprit lesions were identified 
by analyzing the pre-crisis and inter-crisis electrocar-
diograms, left ventricular wall motion abnormalities, and 
angiographic lesion appearances. At 9  months after the 
index stent procedure, we performed the follow-up coro-
nary angiography and OCT examinations of the stented 
segment, and evaluated the incidence of major adverse 
cardiovascular events (MACE) (Fig. 2).
All patients were advised to take dual antiplatelet ther-
apy, which consisted of acetylsalicylic acid (100 mg/day) 
and clopidogrel (75 mg/day) for at least 12 months after 
EES implantation. However, there were no changes in the 
treatments for controlling diabetes, lipids, and hyperten-
sion before the 9-month follow-up.
Continuous glucose monitoring and analysis of glucose 
fluctuations
The CGM system has been described in the previous 
study [16]. In brief, CGM was performed for 3 consecu-
tive days before PCI, and the median variables on days 
2 and 3 [24-h mean glucose levels, time in hyper/hypo-
glycemia, and mean amplitude of glycemic excursion 
(MAGE)] were calculated using CGM analysis software 
(CareLink iPro; Medtronic, Northridge, CA, USA). In 
this context, Service et al. [17] have proposed that MAGE 
represents the fluctuations in blood glucose levels over 
a 24-h period, and MAGE was calculated in the present 
study using the daily variations in blood glucose levels 
(recording using CGM over a 2-day period). All patients 
received optimal meals during the CGM (25–28 kcal/kg 
of ideal body weight; 60 % carbohydrates, 15–20 % pro-
tein, and 20–25 % fat).
Pre‑intervention IVUS and VH‑IVUS analysis
At the index PCI procedure, IVUS was used to measure 
a segment of the target vessel that had a minimum length 
Fig. 1 Study flow chart. We enrolled 50 patients who were treated using everolimus‑eluting stent [37 lesions in 29 patients with diabetes mellitus 
(DM) and 23 lesions in 21 patients without DM] and 23 lesions in 21 patients without DM).PCI: percutaneous coronary intervention; CGM: continu‑
ous glucose monitoring; VH‑IVUS: virtual histology intravascular ultrasound; IGT: impaired glucose tolerance; NGT: normal glucose tolerance; OCT: 
optical coherence tomography
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of 30 mm and extended from the distal side of the target 
lesion to the coronary ostium. The manual contour 
detection in both the lumen and the media adventitia 
interface was performed by two experienced analysts 
who were blinded to baseline clinical and angiographic 
lesion characteristics. We analyzed the whole lesion 
volume, and then calculated the volumes of the lumen, 
vessel, and plaque (vessel minus lumen) using Simpson’s 
method. VH-IVUS automatically classified the plaque 
into four major components [fibrous (labeled green), 
fibro-fatty (labeled greenish-yellow), necrotic core (NC; 
labeled red), and dense calcium (labeled white)] [18]. The 
ratio of each plaque component in the culprit lesions was 
expressed as a percentage of the total plaque volume.
OCT examination
The frequency-domain OCT examination was performed 
at 9  months after stenting, as previously reported [14]. 
In brief, a 0.014-in standard guide wire was positioned 
distally in the target vessel, and the frequency-domain 
OCT catheter (C7 or C8 Dragonfly™; St. Jude Medi-
cal, St. Paul, MN, USA) was advanced to the distal end 
of the target lesion. The entire region of interest was 
scanned using the integrated automated pullback device 
(20 mm/s). For image acquisition, blood in the coronary 
artery was replaced with iodine contrast media that was 
continuously flushed using a power injector, which cre-
ates an essentially blood-free environment. The volume 
and infusion flow rates were decided by the operator and 
ranged from 8 to 20 cm3 at 3–7 cm3/s and 400 psi.
OCT analysis
The off-line OCT analysis was performed using dedi-
cated software (LightLab Imaging Inc, Westford, MA, 
USA), and all images were analyzed by independent 
observers who were blinded to the clinical presentation 
and lesion characteristics. For the quantitative analy-
sis, cross-sectional OCT images were analyzed at 1-mm 
intervals. Bifurcation cross-sections with side branches 
were excluded from this analysis. Neointimal thickness 
(NIT) inside each stent strut and stent area was meas-
ured. The stent and lumen areas were manually measured 
and the neointima area was calculated as the stent area 
minus the lumen area. Struts with an NIT of 0 μm were 
defined as uncovered struts. The frequency of uncovered 
struts was calculated as the number of uncovered struts 
divided by the total number of stent struts. To evalu-
ate asymmetrical stent expansion, a stent eccentricity 
index (SEI) was defined as the minimum stent diameter 
divided by the maximum stent diameter in each cross-
section, and the average and minimum SEIs were calcu-
lated for each stent [19]. It can be assumed that vessel 
healing after DES implantation comprise of the amount 
of neointimal growth leading to restenosis and uncovered 
strut which could be a substrate of thrombosis [20, 21]. 
Therefore, we defined vessel healing as the conditions 
of neointimal growth and uncovered struts after stent-
ing. Intracoronary thrombus was defined as an irregular 
mass protruding beyond the stent strut into the lumen, 
with significant attenuation behind the mass [22]. The 
presence of in-stent thrombi required the agreement of 
two independent experienced observers, which provided 
acceptable intra- and inter-observer agreement (intra-
observer, kappa = 0.9; inter-observer, kappa = 0.815).
Three‑dimensional assessment of neointimal distribution
The three-dimensional uniformity of neointima distribu-
tion within the stented segment was evaluated to investi-
gate the association between the variability in neointima 
proliferation and glucose variability [23]. First, the 
lumen and stent contours on the cross-sectional images 
were manually traced at 1-mm intervals. Next, the soft-
ware divided the neointima area (between the stent and 
lumen) into 360 equally spaced circumferential sectors 
(each sector spanned 1°) for each cross-sectional OCT 
image (Fig.  3). In this process, the lumen’s center was 
used as the reference point for sector division. The mean 
NIT in each sector was automatically calculated, and the 
roughness of the neointima (variability in NIT) within 
the whole stent was evaluated based on the standard 
deviation (SD) of the NITs from the same 1°-sector along 
the entire stented segment. Both quantitative coronary 
analysis by coronary angiography (CAG) and IVUS are 
robust tools for the quantification of neointimal tissue, 
Fig. 2 Study protocol. At the index procedure, patients underwent continuous glucose monitoring (CGM) and percutaneous coronary interven‑
tion (PCI) that was guided via virtual histology intravascular ultrasound (VH‑IVUS). We performed follow‑up optical coherence tomography (OCT) at 
9 months after stenting. No changes were made during the study to any of the medications for controlling diabetes, lipids, and hypertension
Page 5 of 14Kuroda et al. Cardiovasc Diabetol  (2016) 15:79 
Page 6 of 14Kuroda et al. Cardiovasc Diabetol  (2016) 15:79 
so the resolution of CAG and IVUS (i.e., 100–150  μm) 
may not be sufficient for detecting a suppressed, small 
degree of neointimal hyperplasia after DES implanta-
tion. OCT has a higher resolution (10–15 μm) and can 
clearly visualize thin neointima and other subtle changes 
in vascular response in more detail; therefore, we used 
an OCT-based 3-D method to quantitatively evaluate 
the variability in neointimal distribution after stenting to 
investigate the uniformity of neointima proliferation.
Outcome variables and definitions
Clinical outcome data (mean follow-up: 277  days) 
were obtained by reviewing outpatient records and via 
telephone interviews. The primary outcomes were death, 
myocardial infarction (MI), stent thrombosis according to 
the ARC definition [24], clinically-driven TLR, and MACE 
(cardiac death, MI, and TLR) at the 9-month follow-up. 
All deaths were considered cardiac-related unless an 
unequivocal non-cardiac cause was established, and all 
events were carefully verified by independent clinicians.
Statistical analysis
All data were presented as mean ± standard deviation 
or proportions. Variables were compared using Fisher’s 
exact test and Student’s t test, as appropriate. Linear 
mixed effect models were used to explore the influence 
of different variables on variability in NIT and the per-
centage of uncovered struts and to adjust for covari-
ates. Univariabale analysis was first performed, and all 
the variables that satisfied P < 0.1 were entered en bloc 
in the multivariable model, along with age and sex as 
background variables. To assess the inter- and intra-
observer variabilities, the results were compared using 
the kappa test of concordance for categorical data, and 
a Bland–Altman plot was used for continuous data. 
All analyses were performed using SPSS software (ver-
sion 22; SPSS Inc., Chicago, IL, USA), and differences 




We enrolled 50 patients (Fig. 1), and their baseline char-
acteristics are shown in Table 1. There were no significant 
differences between the DM and non-DM groups, 
except for in their levels of HbA1c, 1,5 anhydroglucitol, 
and glycoalbumin. Both groups exhibited similar medi-
cations at admission, with the exception of anti-diabetes 
treatment. However, the DM group typically exhibited 
significantly greater CGM-related values, compared to 
the non-DM group. There were no significant differ-
ences in the minimum blood glucose levels and time in 
hypoglycemia.
Lesion characteristics
The 50 patients had 60 lesions, which included 37 lesions 
in 29 patients with DM and 23 lesions in 21 patients with-
out DM. The plaque characteristics that were obtained 
via VH-IVUS are shown in Table  2. The percentage of 
necrotic core volume within the plaque was numerically 
higher in the DM group, compared to that in the non-
DM group. Stent length in the DM group was longer than 
that in the non-DM group.
OCT measurements
The 9-month OCT revealed that the DM group exhibited 
trends toward a smaller mean stent area, minimum stent 
area, and lumen area. The mean NIT and neointimal area 
were numerically higher in the DM group, compared 
to those in the non-DM group (Table  3). In addition, 
the DM group exhibited a trend towards greater vari-
ability in NIT, compared to the non-DM group. The fre-
quency of uncovered struts was similar between the two 
groups, although the DM group exhibited a marginally 
higher frequency of thrombus attachment (13.5 vs. 0.0 %, 
P = 0.08). In addition, patients having lesions with intra-
stent thrombus showed significantly higher MAGE than 
those without thrombus (103 ± 25 vs. 68 ± 34; P = 0.027, 
respectively).
Associations of OCT measurements with diabetic control 
markers and non‑glycemic metabolic variables
Linear mixed effect models were used to explore the 
influence of different variables on variability in NIT and the 
percentage of uncovered struts and to adjust for covariates. 
Univariable analysis was first performed (Table  4), 
revealed that MAGE was most strongly correlated with 
the previously mentioned OCT measurements (coefficient 
(See figure on previous page.) 
Fig. 3 Three‑dimensional assessment of the neointimal distribution. a The lumen and stent areas were manually traced every 1 mm. b The  
neointimal area was divided into 360 circumferential sectors (each section is 1°, which is referenced from the lumen’s center). The mean neointimal 
thickness (NIT) was calculated for each sector in each 1‑mm section, and the same sector’s thicknesses were compared throughout the entire 
stented segment. c To visualize the two‑dimensional layout, the stent surface was cut along the longitudinal direction and flattened into a  
rectangular shape. The roughness of the neointima (variability in NIT) within the whole stent was evaluated based on the standard deviation (SD) 
of the NITs from the same 1°‑sector along the entire stented segment. Representative cases are shown for a patient with high mean amplitude of 
glycemic excursion (MAGE) (d) and a patient with low MAGE (e)
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Table 1 Baseline patient characteristics
Overall (n = 50) DM (n = 29) Non‑DM (n = 21) P value (DM vs. 
non‑DM)
Age (years) 70.1 ± 10.3 71.6 ± 8.8 68.0 ± 12.1 0.23
BMI (kg/m2) 24.2 ± 3.4 24.5 ± 3.0 23.8 ± 4.0 0.45
Male 43 (86.0) 24 (82.8) 19 (90.5) 0.36
DM 29 (58.0) 29 (100) 0 (0.0) –
Hypertension 37 (74.0) 22 (75.9) 15 (71.4) 0.72
Dyslipidemia 44 (88.0) 27 (93.1) 17 (81.0) 0.19
Smoking 36 (72.0) 21 (72.4) 15 (71.4) 0.38
 Current 10 (20.0) 4 (13.8) 6 (28.6)
 Former (quit >3 months) 26 (52.0) 17 (58.6) 9 (42.9)
Prior myocardial infarction 12 (24.0) 6 (20.7) 6 (28.6) 0.52
Prior PCI 25 (50.0) 16 (55.2) 9 (42.9) 0.39
Systolic blood pressure (mmHg) 122.1 ± 11.8 122.1 ± 11.3 122.1 ± 12.7 0.99
Diastolic blood pressure (mmHg) 63.3 ± 6.9 62.0 ± 6.5 65.2 ± 7.2 0.10
Left ventricular ejection fraction (%) 59.3 ± 10.2 61.7 ± 7.2 55.7 ± 13.0 0.082
Duration of DM (years) 3.4 ± 6.6 7.9 ± 1.5 – –
HbA1c (NGSP) (%) 6.4 ± 0.9 6.8 ± 1.0 5.8 ± 0.3 <0.001
1,5‑AG (μg/mL) 15.7 ± 7.7 13.2 ± 6.7 19.5 ± 7.6 0.004
Glycoalbumin (%) 16.5 ± 3.2 17.6 ± 3.5 14.8 ± 1.8 0.001
75‑g OGTT
 Fasting PG (mg/dL) 102 ± 21 111 ± 23 89 ± 8 <0.001
 2‑h PG (mg/dL) 202 ± 79 249 ± 70 139 ± 33 <0.001
 Fasting IRI (μU/mL) 7.4 ± 6.0 7.9 ± 7.2 6.7 ± 4.0 0.49
 2‑h IRI (μU/mL) 103 ± 106 111 ± 118 91 ± 86 0.53
HOMA R 2.0 ± 2.4 2.4 ± 3.1 1.5 ± 0.8 0.21
HOMA β 80.4 ± 59.7 63.6 ± 40.5 102.7 ± 73.6 0.036
Total cholesterol (mg/dL) 157.0 ± 25.9 157.1 ± 23.6 156.8 ± 29.4 0.96
LDL cholesterol (mg/dL) 88.6 ± 18.1 90.2 ± 17.6 86.2 ± 18.9 0.44
HDL cholesterol (mg/dL) 45.8 ± 12.1 42.6 ± 10.0 50.1 ± 13.6 0.039
Triglyceride (mg/dL) 133.2 ± 53.5 152.55 ± 53.5 107.1 ± 38.6 0.002
CRP (mg/dL) 0.17 ± 0.28 0.14 ± 0.21 0.20 ± 0.34 0.47
Creatinine (mg/dL) 0.98 ± 0.25 0.99 ± 0.24 0.96 ± 0.26 0.63
Medications during the study
 Aspirin 42 (84.0) 25 (86.2) 17 (81.0) 0.45
 Thienopyridine 23 (46.0) 13 (44.8) 10 (47.6) 0.85
 Statin 38 (76.0) 24 (82.8) 14 (66.7) 0.19
 EPA 4 (8.0) 2 (6.9) 2 (9.5) 0.56
 Ezetimibe 4 (8.0) 2 (6.9) 2 (9.5) 0.56
 Fibrate 1 (2.0) 0 (0.0) 1 (4.8) 0.42
 ACE‑I/ARB 27 (54.0) 15 (51.7) 12 (57.1) 0.70
 Beta‑blocker 17 (34.0) 10 (34.5) 7 (33.3) 0.93
 Insulin 0 (0.0)
 Metformin 2 (4.0) 2 (6.9) 0 (0.0) 0.33
 SU 7 (14.0) 7 (24.1) 0 (0.0) 0.016
 α‑GI 3 (6.0) 3 (10.3) 0 (0.0) 0.19
 DPP4‑I 9 (18.0) 9 (18.0) 0 (0.0) 0.004
Continuous glucose monitoring variables
 MAGE (mg/dL) 71 ± 33 80 ± 35 58 ± 28 0.018
 Mean BG (mg/dL) 128 ± 21 137 ± 24 116 ± 9 <0.001
 Max BG (mg/dL) 210 ± 42 226 ± 44 188 ± 27 <0.001
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Values are mean ± standard deviation or number (%). Time in hyperglycemia and hypoglycemia were defined as the time when blood glucose levels were >140 mg/
dL and <70 mg/dL, respectively
1,5-AG 1,5 anhydroglucitol, 75 g OGTT 75-g oral glucose tolerance test, α-GI α-glucosidase inhibitor, ACE-I angiotensin converting enzyme-inhibitor, ARB angiotensin II 
receptor blocker, BG blood glucose, BMI body mass index, CRP C-reactive protein, DM diabetes mellitus, DPP4-I dipeptidyl peptidase-4 inhibitor, EPA eicosapentaenoic 
acid, HbA1c glycated hemoglobin, HDL cholesterol high-density lipoprotein cholesterol, HOMA β homeostasis model assessment beta, HOMA R homeostasis model 
assessment ratio, IRI immunoreactive insulin, LDL cholesterol low-density lipoprotein cholesterol, MAG: mean amplitude of glycemic excursion, NGSP National 
Glycohemoglobin Standardization Program, PCI percutaneous coronary intervention, PG plasma glucose, SU sulfonylureas
Table 1 continued
Overall (n = 50) DM (n = 29) Non‑DM (n = 21) P value (DM vs. 
non‑DM)
 Min BG (mg/dL) 72 ± 23 75 ± 27 70 ± 16 0.62
 Time in hyperglycemia (h) 23.2 ± 24.3 32.9 ± 27.4 9.1 ± 5.6 <0.001
 Time in hypoglycemia (h) 1.7 ± 3.0 1.9 ± 3.5 1.5 ± 2.2 0.62
Table 2 Lesion and procedural characteristics
Values are mean ± standard deviation or number (%)
AHA/ACC American Heart Association/American College of Cardiology, IVUS intravascular ultrasound, LAD left anterior descending artery, LCx left circumflex artery, 
RCA right coronary artery
Overall (n = 60) DM (n = 37) Non‑DM (n = 23) P value (DM vs. 
non‑DM)
Lesion location 0.72
 LAD 26 (43.3) 15 (40.5) 11 (47.8)
 LCx 15 (25.0) 9 (24.3) 6 (26.1)
 RCA 19 (31.2) 13 (35.1) 6 (26.1)
AHA/ACC lesion classification 0.27
 Type A/B1 12 (20.0) 6 (16.2) 6 (26.1)
 Type B2/C 48 (80.0) 31 (83.8) 17 (73.9)
 Chronic total occlusion 8 (13.3) 6 (16.2) 2 (8.7) 0.34
 Bifurcation 16 (26.7) 9 (24.3) 7 (30.4) 0.60
IVUS measurements before stenting
 Plaque volume
  Absolute data (mm3) 98.1 ± 67.7 104.0 ± 77.3 89.2 ± 50.7 0.48
  Plaque burden (%) 58.1 ± 10.5 57.4 ± 11.7 59.2 ± 8.4 0.62
 Lesion length (mm) 14.4 ± 9.1 14..7 ± 10.3 14.0 ± 7.1 0.81
Fibrous
 Absolute data (mm3) 35.1 ± 25.8 37.6 ± 29.0 31.4 ± 20.3 0.44
 Relative data (%) 60.4 ± 9.2 60.6 ± 10.0 59.9 ± 8.2 0.80
Fibro‑fatty
 Absolute data (mm3) 7.3 ± 5.5 7.8 ± 6.3 6.5 ± 4.0 0.41
 Relative data (%) 12.7 ± 5.2 12.1 ± 3.8 13.6 ± 6.8 0.37
Dense‑calcium
 Absolute data (mm3) 5.2 ± 5.4 5.5 ± 6.1 4.7 ± 4.2 0.61
 Relative data (%) 7.7 ± 6.0 7.4 ± 5.8 8.3 ± 6.5 0.64
Necrotic‑core
 Absolute data (mm3) 12.9 ± 12.4 14.4 ± 14.1 10.7 ± 9.4 0.34
 Relative data (%) 19.1 ± 5.3 19.8 ± 4.6 18.2 ± 6.1 0.33
Procedural characteristics
 Stent length (mm) 27.2 ± 13.7 30.2 ± 15.8 22.3 ± 7.4 0.011
 Stent size (mm) 3.0 ± 0.4 2.9 ± 0.4 3.1 ± 0.4 0.14
 Maximum inflation pressure (atm) 11.1 ± 1.4 11.2 ± 1.3 11.0 ± 1.6 0.55
 Overlap stenting 11 (18.3) 10 (27.0) 1 (4.3) 0.026
 Post‑dilatation 47 (78.3) 27 (73.0) 20 (87.0) 0.17
 Rotablation 6 (10.0) 5 (13.5) 1 (4.3) 0.25
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β  ±  standard error  =  0.267  ±  0.073 and 0.016  ±  0.003, 
t = 3.668 and 6.092, both P < 0.001, respectively). However, 
none of the other clinical and laboratory data than glycemic 
variables were correlated with any OCT measurements. 
All the variables that satisfied P  <  0.1 were entered en 
bloc in the multivariable model, along with age and sex as 
background variables (Table  5). As a result, the model of 
variability in NIT was adjusted for age, sex, MAGE, time in 
hypoglycemia, and HOMA R, and the model of percentage 
of uncovered struts by age, sex, MAGE, 1,5 AG, and time 
in hypoglycemia. In the multivariable, a higher MAGE 
was independently associated with greater variability in 
NIT and a higher frequency of uncovered stent struts 
(coefficient β  ±  standard error  =  0.239  ±  0.093 and 
0.019 ± 0.004, t = 2.564 and 4.869, P = 0.014 and <0.001, 
respectively).
Association between plaque characteristics and follow‑up 
OCT findings
We investigated the association between the underlying 
plaque characteristics, as obtained via IVUS at the index 
PCI, and the 9-month OCT findings. A significant cor-
relation was observed between the percentage of necrotic 
core volume within the plaque and the percentage of 
uncovered struts (r = 0.415, P = 0.005), although the per-
centage of necrotic core volume within the plaque was 
not associated with maximum NIT and variability in NIT.
Clinical outcomes
The clinical outcomes at 9 months were available for all 
50 patients (Table  6), and five lesions in four patients 
required TLR (10.0  %) at a mean duration of 311  days 
after EES implantation. There were no cases of cardiac-
related death, MI, or stent thrombosis; thus, the inci-
dence of MACE was 10.0  % at 9  months. Compared to 
non-MACE cases, cases of MACE exhibited a signifi-
cantly higher MAGE, maximum NIT, and variability in 
NIT, although there was no significant difference in these 
groups’ HbA1c levels (Fig. 4).
Discussion
The present study investigated the effects of glucose 
fluctuation on vessel healing after second-generation DES 
implantation in patients with CAD who were receiving 
dyslipidemia treatments. Our main findings are: (1) 
among patients with CAD and dyslipidemia management 
who are referred for PCI, large glucose fluctuations are 
an independent risk factor for impaired uniform vessel 
healing after second-generation DES implantation; and 
(2) compared to non-MACE cases, patients with MACE 
had a higher incidence of delayed vessel healing, which 
was accompanied by larger glucose fluctuations.
The relationship between glucose fluctuation and arterial 
response after stenting
Despite DES’ efficacy in reducing neointimal proliferation 
and restenosis, DES failure and restenosis still occur and 
are more frequent among patients with abnormal glucose 
torelance [25]. Furthermore, unfavorable neointimal 
proliferation, as assessed using OCT, is more common 
among patients with DM [26, 27]. Moreover, diabetes is 
associated with hormonal and vascular abnormalities that 
Table 3 Optical coherence tomography measurements
Values are mean ± standard deviation or number (%)
OCT optical coherence tomography, SEI stent eccentricity index
Overall (n = 60) DM (n = 37) Non‑DM (n = 23) P value (DM vs. 
non‑DM)
OCT follow‑up duration (days) 277 ± 69 287 ± 77 261 ± 51 0.16
Mean stent area (mm2) 6.7 ± 1.9 6.3 ± 1.8 7.2 ± 1.9 0.063
Mean minimum stent area (mm2) 5.3 ± 1.8 5.0 ± 1.7 5.8 ± 1.7 0.073
Mean SEI 0.89 ± 0.03 0.90 ± 0.03 0.88 ± 0.02 0.060
Average of minimum SEI 0.79 ± 0.07 0.79 ± 0.07 0.78 ± 0.06 0.52
Mean lumen area (mm2) 6.1 ± 1.9 5.7 ± 1.77 6.7 ± 1.9 0.051
Mean number of struts 271 ± 112 292 ± 124 237 ± 83 0.070
Mean number of uncovered struts 2.2 ± 2.9 2.4 ± 3.2 1.9 ± 2.2 0.47
Frequency of uncovered struts (%) 0.78 0.79 0.78 0.97
Mean neointimal thickness (µm) 82 ± 35 86 ± 36 75 ± 33 0.28
Mean neointima area (mm2) 0.63 ± 0.31 0.65 ± 0.29 0.61 ± 0.35 0.60
Average of max neointimal thickness (µm) 350 ± 180 420 ± 180 380 ± 150 0.44
Variability in neointima thickness 67 ± 26 73 ± 29 59 ± 18 0.060
Frequency of stent with in‑stent thrombi 5 (8.3) 5 (13.5) 0 (0.0) 0.080
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promote smooth muscle cell proliferation after vascular 
injury, which includes injury after coronary interventions 
[28]. However, it remains unknown regarding what factors 
have the greatest effect on vessel reactions to DES in 
patients with DM. The present study revealed that glucose 
fluctuations had a stronger positive correlation with 
distorted neointimal hyperplasia and incomplete neointimal 
coverage in the stented segment, compared to other glycemic 
variables (e.g., HbA1c), regardless of DM status. Moreover, 
multivariate analysis revealed that glucose fluctuation 
was independently associated with delayed post-stenting 
vessel healing. In this context, increased smooth muscle 
proliferation in patients with diabetes might be caused by 
mitogens (such as platelet-derived growth factor and insulin-
like growth factor) that stimulate cell growth, as well as the 
deleterious effects of endothelial dysfunction and excessive 
extracellular matrix production [29, 30]. Furthermore, recent 
studies have suggested that large glucose fluctuations are 
associated with pro-atherogenic factors, such as oxidative 
stress, inflammation, and endothelial dysfunction; this 
relationship was not observed for sustained hyperglycemia 
that is indicated by HbA1c and fasting plasma glucose 
[8, 31]. Risso et  al. [12] have also explored the effect of 
fluctuating glucose on endothelial cells, and reported that 
apoptosis was enhanced in human endothelial cells that 
were exposed to intermittently high glucose concentrations, 
rather than prolonged hyperglycemic exposure. On the other 
hand, Beusekom et al. [32] reported that stent implantation 
induced endothelial dysfunction in porcine coronary 
arteries. Moreover, in recent studies, it is speculated that 
impaired barrier function of the endothelium in the stented 
segment may allow a greater amount of lipoproteins to 
enter the sub-endothelial space, leading to the development 
of abnormal neointimal growth and atherogenic changes 
[33]. These findings suggest that glucose fluctuations may 
adversely cause endothelial dysfunction in the stented 
segment, leading to the development of abnormal neointimal 
growth and coverage, which supports the findings of the 
present study.
Local arterial healing and future clinical events
Previous studies have demonstrated that DM is 
associated with an increased risk of in-stent restenosis 
and TLR [3, 4, 34]. As its cause, DM is an inflammatory 
proliferative disease that may be susceptible to 
rheological effects, such as the low wall shear stress and 
high oscillatory shear that are caused by turbulent flow, 
which is induced by uneven neointimal distribution 
and may lead to a pro-oxidant, pro-atherosclerotic, and 
pro-coagulative status [35]. These phenomena might be 
accelerated by large glucose fluctuations [8, 12], which 
may explain the heterogeneous neointimal growth 
Table 4 Correlations between optical coherence tomography 
measurements and various metabolic markers
BG blood glucose, CRP C-reactive protein, DM diabetes mellitus, HbA1c glycated 
hemoglobin, HDL cholesterol: high-density lipoprotein cholesterol, HOMA R 
homeostasis model assessment ratio, LDL cholesterol low-density lipoprotein 
cholesterol, MAGE mean amplitude of glycemic excursion, TG triglycerides
Variables Coefficients SE t p value
For variability of NIT
 MAGE 0.267 0.072 3.668 0.0006
 Age −0.071 0.278 −0.258 0.80
 HbA1c 0.867 4.257 0.203 0.83
 1,5 AG −0.403 0.382 −1.054 0.29
 Mean BG 0.210 0.131 1.596 0.11
 Time in hypoglycemia 1.979 0.894 2.214 0.03
 DM duration 0.738 0.473 1.560 0.12
 HOMA R −2.247 1.183 −1.899 0.06
 Male −12.36 8.000 −1.545 0.12
 LDL cholesterol 0.002 0.152 0.018 0.98
 HDL cholesterol 0.243 0.251 0.967 0.33
 TG −0.047 0.052 −0.902 0.37
 CRP −8.176 13.66 −0.598 0.55
For percentage of uncovered struts
 MAGE 0.016 0.002 6.092 <0.0001
 Age 0.020 0.011 1.740 0.11
 HbA1c 0.183 0.180 1.016 0.31
 1,5 AG −0.028 0.016 −1.760 0.084
 Mean BG 0.006 0.005 1.135 0.26
 Time in hypoglycemia 0.072 0.039 1.835 0.072
 DM duration −0.018 0.020 −0.889 0.37
 HOMA R −0.067 0.051 −1.306 0.19
 Male 0.710 0.334 2.122 0.039
 LDL cholesterol 0.002 0.006 0.376 0.70
 HDL cholesterol 0.009 0.010 0.850 0.39
 TG −0.001 0.002 −0.810 0.42
 CRP 0.794 0.576 1.379 0.17
Table 5 Linear mixed effect model adjusted with confound-
ers. (A) Variability in  NIT and  (B) Frequency of  uncovered 
stent struts are the dependent variable
1,5 AG 1,5 anhydroglucitol, HOMA R homeostasis model assessment ratio, MAGE 
mean amplitude of glycemic excursion
Variables Coefficients SE T P value
Variability in neointimal thickness
 MAGE 0.239 0.093 2.564 0.014
 Time in hypoglycemia 0.159 1.060 0.150 0.88
 HOMA R −1.619 1.108 −1.461 0.15
Frequency of uncovered stent struts
 MAGE 0.018 0.004 4.869 <0.0001
 1,5 AG −0.002 0.013 −0.149 0.88
 Time in hypoglycemia −0.057 0.040 −1.405 0.16
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that we observed. For example, all five MACE cases 
exhibited significantly higher MAGE, compared to the 
non-MACE cases. In addition, the variability in NIT was 
significantly greater in the MACE cases, compared to 
the non-MACE cases. Given that the MACE cases only 
involved TLR, our results indicate that large glucose 
fluctuations affected the heterogeneous neointimal 
growth, which may lead to late-phase stent re-stenosis. 
In addition, uneven neointimal distribution is associated 
with intra-stent thrombosis after DES implantation [19]. 
Inhomogeneous neointimal growth coupled with the 
high incidence of thrombus attachment was observed 
in the present study. The previous study has shown 
that yellow plaque detected by angioscopy could be 
associated with intrastent thrombus formation, and 
yellow plaque following DES implantation may reflect 
Table 6 Clinical events
MACE major cardiovascular events, TLR target lesion revascularization





78‑year‑old man 73 5.9 60 0.6 TLR
77‑year‑old man 120 7.8 186 0 TLR
71‑year‑old man 99 6.7 74 0 TLR
71‑year‑old man 99 6.7 100 0.8 TLR
80‑year‑old women 101 6.6 79 0.8 TLR
All MACE cases 99 ± 15 6.7 ± 0.7 100 ± 53 0.4 ± 0.4
Non‑MACE cases 68 ± 34 6.4 ± 0.9 65 ± 21 0.8 ± 0.9
Fig. 4 Comparing cases with and without major adverse cardiac events (MACE). The mean amplitude of glycemic excursion in MACE cases was sig‑
nificantly higher than that in non‑MACE cases (a), whereas the HbA1c levels did not significantly differ between the two groups (b). The maximum 
neointimal thickness (NIT) (c) and variability in NIT (d) were significantly greater in MACE cases, compared to those in non‑MACE cases. There was 
no significant difference between the two groups in the percentage of uncovered struts (e)
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neoatherosclerotic change in the stented segment, which 
might be a risk of late stent failure [36]. Taken together, 
higher variability in NIT after 2nd generation DES 
implantation might cause higher incidence of intrastent 
thrombus, leading to future clinical events.
Several observational studies have reported that strict 
early diabetes control helps prevent macroangiopathy [37], 
which suggests a need for earlier diagnosis and treatment 
of diabetes and glucose intolerance. The present study 
demonstrated that plaque characteristics, which were 
obtained via pre-intervention IVUS, were not associated 
with the variability in NIT but with the percentage of 
uncovered struts after stenting. In our previous studies, 
a large glucose fluctuation is the independent risk factor 
for the development of necrotic core within the coronary 
plaque and formation of TCFA in CAD patients who are 
under treatment for dyslipidemia [10, 16]. The recent study 
demonstrated that uncovered, malapposed, and protruding 
stent struts may be more frequent in vulnerable lesions 
compared with stable lesions after DES implantation [38]. 
These findings seem to indicate that glucose fluctuation 
may promote the formation of unstable plaque, leading to 
more frequent occurrence of uncovered struts after stent 
deployment. In addition, glucose variability was significantly 
and positively correlated with the heterogeneous neointimal 
growth that might be the precursor to late-phase stent 
restenosis. Taken together, controlling glucose fluctuations 
may help avoid heterogeneous neointimal growth and 
unfavorable vessel healing, leading to prevent future clinical 
events in patients with coronary stents. Nevertheless, a 
large-scale prospective study is needed to confirm whether 
additional glucose fluctuation control can decrease the 
incidence of late clinical events.
Limitations
This study had several limitations. First, the single-
center design and relatively small sample size may have 
introduced selection bias. Second, we only assessed 
glycemic variables using CGM at the index procedure, 
and excluded any patients with changes in their 
related medical interventions. However, changes in 
these interventions might affect glycemic metabolism 
and the related follow-up findings. Therefore, future 
studies should examine the effects of changing medical 
interventions on glucose fluctuation, as these changes 
may be relevant to the effect of MAGE on vessel healing 
after stenting. Third, to reduce the influence of the 
patients’ lipid profiles, we excluded patients whose 
LDL cholesterol levels were  >120  mg/dL under statin 
treatment or  >100  mg/dL without statin treatment, and 
only included patients with well-controlled dyslipidemia. 
Fourth, we only included patients who were treated using 
EES. This study indicated that the physicians should use 
EES in this study. However, six patients were treated with 
biolimus-eluting stents by operator’s discretion because 
of lesion length, size and location. Biolimus-eluting stent 
is quite different from EES in regard to stent platform, 
strut thickness, loaded drug, and polymer. Therefore, 
in order to avoid the impact of difference between the 
two stents, we excluded any other second-generation 
DES. Although EES are more effective and safe coronary 
stent than first generation DES, there are DES-specific 
differences among patients with diabetes [39]. Therefore, 
future studies should examine the potential effects of the 
drug, polymer, and stent platform. Fifth, most patients 
with DM were supposed to be in the early stage of DM 
in this study. There were no patients with severe DM, 
including insulin user. A prospective study is warranted 
to evaluate whether glucose fluctuation will have the 
effect of vessel healing after stenting and late clinical 
events in patients with severe DM. Finally, to date, 
direct causal relationship between variability in NIT and 
clinical endpoint has not been proven in patients with 
coronary stents. We used an OCT-based 3-D method 
to quantitatively evaluate the variability in neointimal 
distribution after stenting to investigate the uniformity 
of neointima proliferation. Using this method, large 
glucose fluctuation was associated with higher variability 
in neointimal thickness within the stent, suggesting more 
homogeneous neointimal suppression by the control of 
glucose fluctuation. A sufficiently powered clinical study 
should be performed to more adequately address the true 
impact of variability in NIT on future clinical events.
Conclusions
Glucose fluctuations may affect vessel healing after EES 
implantation in patients with CAD who are receiving 
lipid-lowering therapy. Therefore, glucose fluctuations 
may be an important target for secondary prevention 
after coronary stenting, which is independent of dys-
lipidemia control. Nevertheless, future studies should 
examine the rationale for the early detection and control 
of glucose fluctuations, based on the wide-spread use of 
second-generation DES for patients with CAD.
Abbreviations
CAD: coronary artery disease; CGM: continuous glucose monitoring; DM: 
diabetes mellitus; MACE: major adverse cardiac events; MAGE: mean 
amplitude of glycemic excursion; NIT: neointimal thickness; OCT: optical 
coherence tomography; PCI: percutaneous coronary intervention; VH‑IVUS: 
virtual histology intravascular ultrasound.
Authors’ contributions
All authors were involved in reporting the results of this study and all 
approved the final version of the submitted manuscript. MK, TS, and HO 
contributed in the conception, design and planning of the study. All authors 
were involved in acquisition of data and critical revision of the manuscript 
for important intellectual content. DS, MK and TS did the statistical analysis. 
Manuscript writing: MK and TS. TS is responsible for the overall content and 
serves as guarantor. All authors read and approved the final manuscript.
Page 13 of 14Kuroda et al. Cardiovasc Diabetol  (2016) 15:79 
Author details
1 Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe 
University Graduate School of Medicine, 7‑5‑1 Kusunoki‑cho, Chuo‑Ku, Kobe, 
Hyogo 650‑0017, Japan. 2 Department of Preventive Medicine and Public 
Health, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku‑ku, 
Tokyo 160‑8582, Japan. 3 Division of Diabetes and Metabolism, Department 
of Internal Medicine, Kobe University Graduate School of Medicine, 7‑5‑1 
Kusunoki‑cho, Chuo‑Ku, Kobe, Hyogo 650‑0017, Japan. 
Acknowledgements
The authors thank Ms. Moe Kitamura for her excellent technical assistance 
with the CGM, as well as Mr. Naoki Matsukawa, Kazuki Komaru, Keiji Notomi, 
and Yahiro Ikari from MICRON Inc. for their assistance with the OCT analysis.
Competing interests
The authors declare that they have no competing interests.
Funding
There is no grant support for this manuscript.
Received: 16 February 2016   Accepted: 10 May 2016
References
 1. Schömig A, Mehilli J, Holle H, et al. Statin treatment following coronary 
artery stenting and 1‑year survival. J Am Coll Cardiol. 2002;40(5):8.
 2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKil‑
lop JH, Packard CJ. Prevention of coronary heart disease with pravastatin 
in men with hypercholesterolemia. West of Scotland Coronary Prevention 
Study Group. N Engl J Med. 1995;333(20):1301–7.
 3. Kumar R, Lee TT, Jeremias A, Ruisi CP, Sylvia B, Magallon J, Kirtane AJ, 
Bigelow B, Abrahamson M, Pinto DS, et al. Comparison of outcomes 
using sirolimus‑eluting stenting in diabetic versus nondiabetic patients 
with comparison of insulin versus non‑insulin therapy in the diabetic 
patients. Am J Cardiol. 2007;100(8):1187–91.
 4. Machecourt J, Danchin N, Lablanche JM, Fauvel JM, Bonnet JL, Marliere 
S, Foote A, Quesada JL, Eltchaninoff H, Vanzetto G. Risk factors for stent 
thrombosis after implantation of sirolimus‑eluting stents in diabetic and 
nondiabetic patients: the EVASTENT matched‑cohort registry. J Am Coll 
Cardiol. 2007;50(6):501–8.
 5. West NE, Ruygrok PN, Disco CM, Webster MW, Lindeboom WK, O’Neill 
WW, Mercado NF, Serruys PW. Clinical and angiographic predictors 
of restenosis after stent deployment in diabetic patients. Circulation. 
2004;109(7):867–73.
 6. Uetani T, Amano T, Harada K, Kitagawa K, Kunimura A, Shimbo Y, Harada 
K, Yoshida T, Kato B, Kato M, et al. Impact of insulin resistance on post‑
procedural myocardial injury and clinical outcomes in patients who 
underwent elective coronary interventions with drug‑eluting stents. 
JACC Cardiovasc Interv. 2012;5(11):1159–67.
 7. Kedhi E, Gomes ME, Lagerqvist B, Smith JG, Omerovic E, James S, Harnek 
J, Olivecrona GK. Clinical impact of second‑generation everolimus‑elut‑
ing stent compared with first‑generation drug‑eluting stents in diabetes 
mellitus patients: insights from a nationwide coronary intervention 
register. JACC Cardiovasc Interv. 2012;5(11):1141–9.
 8. Louis Monnier M. Activation of oxidative stress by acute glucose fluctua‑
tions compared with sustained chronic hyperglycemia in patientswith 
type 2 diabetes. JAMA. 2006;296(14):1681–7.
 9. The DECODE study group on behalf of the. Europe an Diabetes 
Epidemiology Group: glucose tolerance and mortality: comparison of 
WHO and American Diabetic Association diagnostic criteria. Lancet. 
1999;354(9179):617–21.
 10. Kuroda M, Shinke T, Sakaguchi K, Otake H, Takaya T, Hirota Y, Osue T, 
Kinutani H, Konishi A, Takahashi H, et al. Association between daily 
glucose fluctuation and coronary plaque properties in patients receiv‑
ing adequate lipid‑lowering therapy assessed by continuous glucose 
monitoring and optical coherence tomography. Cardiovasc Diabetol. 
2015;14:78.
 11. Okada K, Hibi K, Gohbara M, Kataoka S, Takano K, Akiyama E, Matsuzawa 
Y, Saka K, Maejima N, Endo M, et al. Association between blood glucose 
variability and coronary plaque instability in patients with acute coronary 
syndromes. Cardiovasc Diabetol. 2015;14:111.
 12. Risso A. Intermittent high glucose enhances apoptosis in human umbili‑
cal vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 
2001;281:E924–30.
 13. Komatsu T, Yaguchi I, Komatsu S, Nakahara S, Kobayashi S, Sakai Y, 
Taguchi I. Impact of insulin resistance on neointimal tissue proliferation 
after 2nd‑generation drug‑eluting stent implantation. Tex Heart Inst J. 
2015;42(4):327–32.
 14. Matsumoto D, Shite J, Shinke T, Otake H, Tanino Y, Ogasawara D, Sawada 
T, Paredes OL, Hirata K, Yokoyama M. Neointimal coverage of sirolimus‑
eluting stents at 6‑month follow‑up: evaluated by optical coherence 
tomography. Eur Heart J. 2007;28(8):961–7.
 15. Burgmaier M, Hellmich M, Marx N, Reith S. A score to quantify coronary 
plaque vulnerability in high‑risk patients with type 2 diabetes: an optical 
coherence tomography study. Cardiovasc Diabetol. 2014;13:117.
 16. Kuroda M, Shinke T, Sakaguchi K, Otake H, Takaya T, Hirota Y, Sugiyama D, 
Nakagawa M, Hariki H, Inoue T, et al. Effect of daily glucose fluctuation on 
coronary plaque vulnerability in patients pre‑treated with lipid‑lowering 
therapy: a prospective observational study. JACC Cardiovasc Interv. 
2015;8(6):800–11.
 17. Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. 
Mean amplitude of glycemic excursions, a measure of diabetic instability. 
Diabetes. 1970;19(9):644–55.
 18. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coro‑
nary plaque classification with intravascular ultrasound radiofrequency 
data analysis. Circulation. 2002;106(17):2200–6.
 19. Otake H, Shite J, Ako J, Shinke T, Tanino Y, Ogasawara D, Sawada T, Miyoshi 
N, Kato H, Koo BK, et al. Local determinants of thrombus formation 
following sirolimus‑eluting stent implantation assessed by optical coher‑
ence tomography. JACC Cardiovasc Interv. 2009;2(5):459–66.
 20. Suzuki Y, Ikeno F, Koizumi T, Tio F, Yeung AC, Yock PG, Fitzgerald PJ, 
Fearon WF. In vivo comparison between optical coherence tomog‑
raphy and intravascular ultrasound for detecting small degrees of 
in‑stent neointima after stent implantation. JACC Cardiovasc Interv. 
2008;1(2):168–73.
 21. Karanasos A, Ligthart J, Witberg K, van Soest G, Bruining N, Regar E. 
Optical coherence tomography: potential clinical applications. Curr 
Cardiovasc Imaging Rep. 2012;5(4):206–20.
 22. Jang IK, Tearney GJ, MacNeill B, Takano M, Moselewski F, Iftima N, 
Shishkov M, Houser S, Aretz HT, Halpern EF, et al. In vivo characterization 
of coronary atherosclerotic plaque by use of optical coherence tomogra‑
phy. Circulation. 2005;111(12):1551–5.
 23. Otake H, Shite J, Shinke T, Miyoshi N, Kozuki A, Kawamori H, Nakagawa M, 
Nagoshi R, Hariki H, Inoue T, et al. Impact of stent platform of paclitaxel‑
eluting stents: assessment of neointimal distribution on optical coher‑
ence tomography. Circ J. 2012;76(8):1880–8.
 24. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, 
Steg PG, Morel MA, Mauri L, Vranckx P, et al. Clinical end points in 
coronary stent trials: a case for standardized definitions. Circulation. 
2007;115(17):2344–51.
 25. Costa MA, Simon DI. Molecular basis of restenosis and drug‑eluting 
stents. Circulation. 2005;111(17):2257–73.
 26. Tanaka N, Terashima M, Rathore S, Itoh T, Habara M, Nasu K, Kimura M, 
Itoh T, Kinoshita Y, Ehara M, et al. Different patterns of vascular response 
between patients with or without diabetes mellitus after drug‑eluting 
stent implantation: optical coherence tomographic analysis. JACC Cardio‑
vasc Interv. 2010;3(10):1074–9.
 27. Nusca A, Patti G, Marino F, Mangiacapra F, D’Ambrosio A, Di Sciascio G. 
Prognostic role of preprocedural glucose levels on short‑ and long‑term 
outcome in patients undergoing percutaneous coronary revasculariza‑
tion. Catheter Cardiovasc Interv. 2012;80(3):377–84.
 28. Aronson D, Bloomgarden Z, Rayfield EJ. Potential mechanisms promoting 
restenosis in diabetic patients. J Am Coll Cardiol. 1996;27(3):8.
 29. Kanzaki T, Shinomiya M, Ueda S, Morisaki N, Saito Y, Yoshida S. Enhanced 
arterial intimal thickening after balloon catheter injury in diabetic animals 
accompanied by PDGF beta‑receptor overexpression of aortic media. Eur 
J Clin Invest. 1994;24(6):377–81.
Page 14 of 14Kuroda et al. Cardiovasc Diabetol  (2016) 15:79 
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
 30. Kirstein M, Brett J, Radoff S, Ogawa S, Stern D, Vlassara H. Advanced 
protein glycosylation induces transendothelial human monocyte chemo‑
taxis and secretion of platelet‑derived growth factor: role in vascular dis‑
ease of diabetes and aging. Proc Natl Acad Sci U S A. 1990;87(22):9010–4.
 31. Chen XM, Zhang Y, Shen XP, Huang Q, Ma H, Huang YL, Zhang WQ, Wu 
HJ. Correlation between glucose fluctuations and carotid intima‑media 
thickness in type 2 diabetes. Diabetes Res Clin Pract. 2010;90(1):95–9.
 32. van Beusekom HM, Whelan DM, Hofma SH, Krabbendam SC, van 
Hinsbergh VW, Verdouw PD, van der Giessen WJ. Long‑term endothelial 
dysfunction is more pronounced after stenting than after balloon angio‑
plasty in porcine coronary arteries. J Am Coll Cardiol. 1998;32(4):1109–17.
 33. Otsuka F, Byrne RA, Yahagi K, Mori H, Ladich E, Fowler DR, Kutys R, Xhepa 
E, Kastrati A, Virmani R, et al. Neoatherosclerosis: overview of histopatho‑
logic findings and implications for intravascular imaging assessment. Eur 
Heart J. 2015;36(32):2147–59.
 34. Hong SJ, Kim MH, Ahn TH, Ahn YK, Bae JH, Shim WJ, Ro YM, Lim DS. Multi‑
ple predictors of coronary restenosis after drug‑eluting stent implanta‑
tion in patients with diabetes. Heart. 2006;92(8):1119–24.
 35. Malek AM, Alper SL, Izumo S. Hemodynamic shear stress and its role in 
atherosclerosis. JAMA. 1999;282(21):2035–42.
 36. Ichikawa M, Takei Y, Hamasaki T, Kijima Y. Characterization of patients 
with angioscopically‑detected in‑stent mural thrombi—genetics of 
clopidogrel responsiveness and generations of drug‑eluting stents. Circ J. 
2015;79(1):85–90.
 37. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10‑year follow‑
up of intensive glucose control in type 2 diabetes. N Engl J Med. 
2008;359(15):1577–89.
 38. Raber L, Zanchin T, Baumgartner S, Taniwaki M, Kalesan B, Moschovitis A, 
Garcia‑Garcia HM, Justiz J, Pilgrim T, Wenaweser P, et al. Differential heal‑
ing response attributed to culprit lesions of patients with acute coronary 
syndromes and stable coronary artery after implantation of drug‑
eluting stents: an optical coherence tomography study. Int J Cardiol. 
2014;173(2):259–67.
 39. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, Wil‑
liams DO, Slater J, Cutlip DE, Feit F. Outcomes with various drug eluting 
or bare metal stents in patients with diabetes mellitus: mixed treat‑
ment comparison analysis of 22,844 patient years of follow‑up from 
randomised trials. BMJ. 2012;345:e5170.
